Review
Otorhinolaryngology
Sharmila Dhulipalla
Summary: This systematic review examines the effectiveness and safety of sublingual immunotherapy for allergic rhinoconjunctivitis caused by Ragweed. The results suggest that sublingual immunotherapy can improve symptoms, but more high-quality studies are needed to determine optimal dosing strategies.
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY
(2022)
Review
Immunology
Zao Ji, Feifei Jiang
Summary: This study systematically evaluated the clinical efficacy and safety of sublingual immunotherapy for allergic rhinitis. The findings showed that sublingual immunotherapy has better efficacy and safety compared to traditional medicine.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Shaobing Xie, Sijie Jiang, Hua Zhang, Fengjun Wang, Yongzhen Liu, Yongchuan She, Qiancheng Jing, Kelei Gao, Ruohao Fan, Shumin Xie, Zhihai Xie, Weihong Jiang
Summary: This study identified several serum biomarkers through metabolomics analysis that can reliably predict the efficacy of ASIT in AR patients, with these biomarkers mainly involving glycolysis, fatty acid metabolism, and other metabolic pathways.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2021)
Review
Allergy
Wenping Wang, Xiaoyan Wang, Hongtian Wang, Xueyan Wang
Summary: This systematic review and meta-analysis evaluated the safety and efficacy of intralymphatic immunotherapy (ILIT) for allergic rhinoconjunctivitis (ARC). The results showed that ILIT was safe and had comparable clinical improvement to subcutaneous immunotherapy (SCIT). ILIT had a higher incidence of local adverse events compared to placebo, but its overall adverse event profile was similar to placebo. ILIT was also safer and had higher compliance compared to SCIT.
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY
(2023)
Article
Allergy
Wenlong Liu, Qingxiang Zeng, Chunhui He, Rongshan Chen, Yiquan Tang, Shengbao Yan, Xi Luo, Renzhong Luo
Summary: The study compared the efficacy, safety, and compliance of SCIT and SLIT in children with allergic rhinitis. Results indicated that SCIT was more effective than SLIT to a certain degree but had higher occurrence of adverse events. Individuals can choose the appropriate AIT route based on their specific conditions.
PEDIATRIC ALLERGY AND IMMUNOLOGY
(2021)
Review
Allergy
Prapasri Kulalert, Phichayut Phinyo, Mongkol Lao-Araya
Summary: HDM-SLIT tablets are an effective treatment for allergic rhinitis, reducing symptom scores and medication use, improving quality of life and conjunctivitis symptoms.
WORLD ALLERGY ORGANIZATION JOURNAL
(2022)
Review
Medicine, Research & Experimental
Kevin Tie, Craig Miller, Adam M. Zanation, Charles S. Ebert
Summary: The study found that SCIT and SLIT are equally effective treatments for adults with AR/C, but more randomized controlled trials are needed to directly compare the two methods.
Article
Allergy
Edwin H. Kim, Corinne A. Keet, Yamini V. Virkud, Stacy Chin, Ping Ye, Anusha Penumarti, Johanna Smeekens, Rishu Guo, Xiaohong Yue, Quefeng Li, Michael R. Kosorok, Michael D. Kulis, Wesley Burks
Summary: This study evaluated the efficacy and safety of 4-mg peanut sublingual immunotherapy (SLIT) and the persistence of desensitization after discontinuation of SLIT. The results showed that most children achieved significant desensitization during SLIT and it lasted for more than 17 weeks after discontinuation. This study demonstrates that peanut SLIT is safe and effective.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
(2023)
Review
Allergy
Nor Rahimah Aini, Norhayati Noor, Mohd Khairi Md Daud, Sarah K. Wise, Baharudin Abdullah
Summary: Intralymphatic immunotherapy may have a role in treating allergic rhinitis patients, but based on the review results, it is considered safe but not significantly effective. Future trials with larger sample sizes and standardized administration and outcome measures are recommended.
CLINICAL AND TRANSLATIONAL ALLERGY
(2021)
Review
Otorhinolaryngology
Dijiang Ma, Qiling Zheng, Jianing Sun, Shenjun Tang, Wudan He
Summary: The findings of this meta-analysis indicate that sublingual immunotherapy (SLIT) may be a therapeutic approach to improve symptoms of allergic rhinitis and asthma in patients with asthma. However, further high-quality and well-designed studies are needed to clarify the efficacy of SLIT due to significant heterogeneity in the results.
AMERICAN JOURNAL OF RHINOLOGY & ALLERGY
(2023)
Article
Otorhinolaryngology
Feng Yan, Yingzi Cao, Liu Ying, Wang Qian, He Chan, Jianli Hao, Kejun Zhang, HuangFu Hui
Summary: This study aimed to assess the feasibility of using coseasonal-initiated Artemisia annua sublingual immunotherapy (SLIT) for treating seasonal allergic rhinoconjunctivitis (SARC). The results showed that after one year of SLIT treatment, the symptoms of SARC patients were significantly improved and the treatment was relatively safe.
AMERICAN JOURNAL OF OTOLARYNGOLOGY
(2023)
Article
Immunology
Yanni Zhang, Kang Zhu, Hui Lv, Jingguo Chen, Chao Yu, Tianxi Gao, Jing Yan, Fangli Yang, Lina Fan, Xiaoyong Ren, Cui Xia
Summary: This study found that serum exosome-derived miR-146a-3p may serve as a novel biomarker for predicting the short and long-term efficacies of sublingual immunotherapy (SLIT) in allergic rhinitis (AR) patients.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Medicine, General & Internal
Maria Aranzazu Martin Iglesias, Rosa Garcia Rodriguez, Alberto Palacios Canas, Jaime Vinicio Meneses Sotomayor, Miriam Clar Castello, Francisco Feo Brito
Summary: This study evaluated a new treatment option for LTP syndrome, which involved SLIT-peach followed by OIT with commercial peach juice. The results demonstrated that this protocol was safe and effective, improving the quality of life for patients.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Allergy
Jin Youp Kim, Myoung-Jin Jang, Dong-Young Kim, Seok-Won Park, Doo Hee Han
Summary: This study compared the efficacy of SLIT drops, SLIT tablets, and SCIT in patients with perennial allergic rhinitis through network analysis. The results demonstrated that all immunotherapy modalities significantly reduced symptom and medication scores, with SCIT possibly being more effective in controlling symptoms compared to SLIT drops or tablets.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2021)
Article
Otorhinolaryngology
Wanting Zhu, Pei Gao, Qidi Zhang, Jianjun Chen
Summary: Meta-analysis showed that subcutaneous immunotherapy (SCIT) has a significant effect on improving symptoms and reducing medicine consumption for local allergic rhinitis (LAR) patients. Larger and multicenter clinical trials are needed to clarify the safety and long-term efficacy.
AMERICAN JOURNAL OF RHINOLOGY & ALLERGY
(2022)
Article
Allergy
Giorgio Walter Canonica, Tim W. Harrison, Pascal Chanez, Francesco Menzella, Renaud Louis, Borja G. Cosio, Njira L. Lugogo, Arjun Mohan, Annie Burden, Esther Garcia Gil
Summary: The study showed that benralizumab can improve symptoms of NP and asthma outcomes in patients with severe, eosinophilic asthma and NP, with better effects observed in patients with high baseline SNOT-22 scores.
Article
Allergy
Joaquim Mullol, Tanya M. Laidlaw, Claus Bachert, Leda P. Mannent, G. Walter Canonica, Joseph K. Han, Jorge F. Maspero, Cesar Picado, Nadia Daizadeh, Benjamin Ortiz, Yongtao Li, Marcella Ruddy, Elizabeth Laws, Nikhil Amin
Summary: In patients with difficult-to-treat CRSwNP, dupilumab significantly improved objective measures and patient-reported symptoms to a greater extent in the presence of comorbid NSAID-ERD than without. Dupilumab was well tolerated in patients with/without NSAID-ERD.
Article
Allergy
Fulvio Braido, Francesco Blasi, Giorgio Walter Canonica, Pierluigi Paggiaro, Bianca Beghe, Matteo Bonini, Giovanna Elisiana Carpagnano, Stefano Del Giacco, Federico Lavorini, Manlio Milanese, Vincenzo Patella, Pierachille Santus, Marco Contoli
Summary: This study in Italy aims to investigate the clinical status and disease progression of patients with mild-to-moderate asthma, analyzing the epidemiological evolution and treatment response through observational research, exploring the impact of environmental and lifestyle factors on asthma.
Article
Allergy
Ekaterina Potapova, Veronique Bordas-Le Floch, Thomas Schlederer, Susanne Vrtala, Huey-Jy Huang, Giorgio W. Canonica, Rudolf Valenta, Paolo M. Matricardi, Laurent Mascarell
Summary: Background: The molecular antibody reactivity profiles in sublingual house dust mite (HDM) tablet immunotherapy have not been thoroughly studied. Our study used allergen microarray technology to examine the humoral immune responses to a variety of HDM allergens and found that specific IgE levels to Der p 1 and Der p 23 were significantly associated with asthma. After allergen-specific immunotherapy (AIT), an increase in specific IgG and IgG4 antibodies to Der p 1, Der p 2, and Der p 23 was observed, indicating the induction of specific antibodies by sublingual AIT.
Article
Cardiac & Cardiovascular Systems
Kenneth R. Chapman, Giorgio Walter Canonica, Kim L. Lavoie, Natalia Nenasheva, Gabriel Garcia, Sinthia Bosnic-Anticevich, Arnaud Bourdin, Maria Carmen del Cano, P. G. Abhijith, Bhumika Aggarwal
Summary: According to the 2021 GINA report, physicians tend to prefer a preventive regular dosing approach for treating patients with moderate to severe asthma, rather than using short-acting beta 2-agonists. However, many patients on the maintenance and reliever therapy (MART) request additional rescue inhalers, suggesting a misapplication of MART therapy.
RESPIRATORY MEDICINE
(2022)
Editorial Material
Otorhinolaryngology
Francesco Giombi, Alejandra Carron-Herrero, Francesca Pirola, Giovanni Paoletti, Emanuele Nappi, Elena Russo, Armando De Virgilio, Giuseppe Mercante, Giorgio Walter Canonica, Giuseppe Spriano, Enrico Heffler, Luca Malvezzi
INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY
(2022)
Review
Respiratory System
Giovanni Paoletti, Jack Pepys, Marta Casini, Danilo Di Bona, Enrico Heffler, Celine Y. Y. Goh, David B. Price, Giorgio Walter Canonica
Summary: The introduction of novel biologic drugs has revolutionised the treatment of severe asthma, but evaluating their real-life effectiveness is crucial for tailoring the right treatment for patients.
EUROPEAN RESPIRATORY REVIEW
(2022)
Article
Allergy
Jaime Sanchez-Lopez, Enrico Heffler, Giorgio Walter Canonica
Summary: This study aimed to evaluate the impact of the COVID-19 pandemic on the perceptions and administration of allergen immunotherapy (AIT) in Italy. The results showed that Italian physicians did not perceive an added risk of AIT therapy for patients with allergic asthma or rhinitis during the pandemic. However, there was a decrease in the initiation of AIT therapy, and sublingual AIT was preferred over subcutaneous AIT.
ALLERGOLOGIA ET IMMUNOPATHOLOGIA
(2022)
Article
Health Care Sciences & Services
Gabriele Rumi, G. Walter Canonica, Juliet M. Foster, Niels H. Chavannes, Giuseppe Valenti, Rosario Contiguglia, Eleni Rapsomaniki, Janwillem W. H. Kocks, Dario De Brasi, Fulvio Braido
Summary: The study investigates the implementation of the Turbu+ program in community settings to support asthma self-management and medication adherence. The results show high medication adherence, which may be attributed to the use of electronic monitoring and feedback mechanism provided by the Turbu+ program.
JMIR MHEALTH AND UHEALTH
(2022)
Correction
Health Care Sciences & Services
Gabriele Rumi, G. Walter Canonica, Juliet M. Foster, Niels H. Chavannes, Giuseppe Valenti, Rosario Contiguglia, Eleni Rapsomaniki, Janwillem W. H. Kocks, Dario De Brasi, Fulvio Braido
JMIR MHEALTH AND UHEALTH
(2022)
Article
Allergy
Gianenrico Senna, Maria Aliani, Elena Altieri, Pietro Bracciale, Luisa Brussino, Maria Filomena Caiaffa, Paolo Cameli, Giorgio Walter Canonica, Cristiano Caruso, Maria D'Amato, Fausto De Michele, Stefano Del Giacco, Fabiano Di Marco, Francesco Menzella, Girolamo Pelaia, Paola Rogliani, Micaela Romagnoli, Pietro Schino, Jan Walter Schroeder, Alessandra Vultaggio, Sara Rizzoli, Alessandro Zullo, Silvia Boarino, Marilena Palmisano, Alessandra Rossi, Gianfranco Vitiello, Stefano Centanni
Summary: The post hoc analysis from the Italian study ANANKE aimed to define the clinical features and effectiveness of benralizumab in the BEC 300-450 cells/mm3 subset of patients. Results showed that patients in this subset had similar improvements in exacerbation rate, asthma control, lung function, and corticosteroid use after 48 weeks of benralizumab treatment compared to the total population.
JOURNAL OF ASTHMA AND ALLERGY
(2022)
Article
Immunology
Erminia Ridolo, Alessandro Barone, Francesca Nicoletta, Giovanni Paoletti, Enrico Heffler, Luca Malvezzi, Giorgio Walter Canonica
Summary: Allergic rhinitis (AR) is a common disease with a significant impact on quality of life and high management costs. The use of multiple drugs for symptom control in AR patients often leads to poor therapeutic adherence. However, the novel intranasal corticosteroid/antihistamine combination, GSP301, has shown promising efficacy and safety in providing rapid symptom relief and good tolerability.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
(2023)
Article
Immunology
M. K. Church, G. W. Canonica, P. Kuna, M. Maurer, R. Moesges, Z. Novak, N. G. Papadopoulos, P. Rodriguez del Rio
Summary: Allergic rhinoconjunctivitis and chronic urticaria have detrimental effects on cognitive functions, sleep, daily activities, and quality of life. Non-sedating second-generation H-1 antihistamines, including bilastine, are effective treatments for these conditions.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
(2023)
Editorial Material
Allergy
G. Walter Canonica, Ioana Agache, Holger J. Schunemann, Nicolas Roche, David Price, Stefano del Giacco
Review
Respiratory System
Manuela Latorre, Riccardo Pistelli, Giovanna Elisiana Carpagnano, Alessandro Celi, Ilaria Puxeddu, Nicola Scichilone, Antonio Spanevello, Giorgio Walter Canonica, Pierluigi Paggiaro
Summary: This article traces the concept of asthma control within GINA guidelines over the past 25 years. It discusses the shift in focus from controlling all clinical and functional characteristics of asthma to prioritizing the prevention of exacerbations. The importance of symptom control and the relationship between symptoms and exacerbations in moderate-severe asthma are highlighted.
THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE
(2023)
Review
Immunology
Xiangye Zhao, Kewei Ma, Xiaobo Ma, Xu Wang, Chao Sun, Shi Qiu, Ye Guo, Zhiguang Yang, Yunpeng Liu, Yinghui Xu
Summary: Immunotherapy may lead to pseudoprogression, where tumors initially grow but shrink with continued treatment. This article reports a case of pseudoprogression in a lung cancer patient receiving immunotherapy, and reviews the mechanisms, clinical manifestations, and prognostic indicators of pseudoprogression.
Article
Immunology
Ling-zhijie Kong, Ying Zheng, Kaichun Li
Summary: Treatment options for metastatic colorectal cancer are limited after second-line chemotherapy failure. In this case report, a 59-year-old male patient achieved remarkable response to fruquintinib and toripalimab combination therapy after multiple lines of chemotherapy failed. The patient had partial response within 3 months and complete response of pulmonary masses within 12 months. The combination of fruquintinib and PD-1 inhibitors improves the prognosis of metastatic colorectal cancer, with a progression-free survival of over 17 months.
